Trevi Therapeutics, Inc. — All Filings
513 total filings on record
Public companies registered with the SEC are required to file periodic reports, disclosures, and notices throughout the year. The most important are the 10-K (annual report), 10-Q (quarterly report), and 8-K (material event notice). Use the filters below to narrow by form type.
All
10-K
10-Q
144
144/A
3
4
4/A
424B3
424B4
424B5
5
8-A12B
8-K
ARS
CERT
CORRESP
D
D/A
DEF 14A
DEFA14A
DRS
DRS/A
DRSLTR
EFFECT
FWP
PRE 14A
RW
S-1
S-1/A
S-3
S-3/A
S-3ASR
S-8
SC 13D
SC 13D/A
SC 13G
SC 13G/A
SCHEDULE 13D/A
SCHEDULE 13G
SCHEDULE 13G/A
UPLOAD
| Form | Description | Accession Number | Filed | Period |
|---|---|---|---|---|
| 4 | 4 | 0000950170-25-080883 | Jun 3, 2025 | May 31, 2025 |
| 4 | 4 | 0000950170-25-080887 | Jun 3, 2025 | May 31, 2025 |
| 4 | 4 | 0000950170-25-080889 | Jun 3, 2025 | May 31, 2025 |
| 4 | 4 | 0000950170-25-080885 | Jun 3, 2025 | May 31, 2025 |
| 8-K | 8-K | 0001193125-25-132890 | Jun 2, 2025 | — |
| 8-K | 8-K | 0001193125-25-133273 | Jun 2, 2025 | — |
| 424B5 | 424B5 | 0001193125-25-133344 | Jun 2, 2025 | — |
| SCHEDULE 13G/A | — | 0000905148-25-001760 | May 15, 2025 | — |
| SCHEDULE 13G/A | — | 0001415889-25-012996 | May 15, 2025 | — |
| 8-K | 8-K | 0000950170-25-066971 | May 8, 2025 | — |
| 10-Q | 10-Q | 0000950170-25-067011 | May 8, 2025 | Mar 31, 2025 |
| DEF 14A | DEF 14A | 0000950170-25-059628 | Apr 29, 2025 | — |
| ARS | ARS | 0000950170-25-059635 | Apr 29, 2025 | Dec 31, 2024 |
| DEFA14A | DEFA14A | 0000950170-25-059693 | Apr 29, 2025 | — |
| 4 | 4 | 0000950170-25-045295 | Mar 26, 2025 | Mar 25, 2025 |
| 4 | 4 | 0000950170-25-044436 | Mar 25, 2025 | Mar 21, 2025 |
| 144 | — | 0001972481-25-000060 | Mar 21, 2025 | — |
| SCHEDULE 13D/A | — | 0001072613-25-000239 | Mar 20, 2025 | — |
| 10-K | 10-K | 0000950170-25-041194 | Mar 18, 2025 | Dec 31, 2024 |
| S-8 | S-8 | 0000950170-25-041206 | Mar 18, 2025 | — |
| 8-K | 8-K | 0000950170-25-041187 | Mar 18, 2025 | — |
| 4 | 4 | 0000950170-25-037884 | Mar 12, 2025 | Mar 10, 2025 |
| 4 | 4 | 0000950170-25-037882 | Mar 12, 2025 | Mar 10, 2025 |
| 4 | 4 | 0000950170-25-037886 | Mar 12, 2025 | Mar 10, 2025 |
| 4 | 4 | 0000950170-25-037880 | Mar 12, 2025 | Mar 10, 2025 |
| 4 | 4 | 0000950170-25-037883 | Mar 12, 2025 | Mar 10, 2025 |
| 144 | — | 0001972481-25-000049 | Mar 10, 2025 | — |
| 8-K | 8-K | 0000950170-25-036503 | Mar 10, 2025 | — |
| 4 | 4 | 0000950170-25-024116 | Feb 20, 2025 | Feb 18, 2025 |
| 4 | 4 | 0000950170-25-024111 | Feb 20, 2025 | Feb 18, 2025 |
| 4 | 4 | 0000950170-25-024117 | Feb 20, 2025 | Feb 18, 2025 |
| 4 | 4 | 0000950170-25-024109 | Feb 20, 2025 | Feb 18, 2025 |
| 4 | 4 | 0000950170-25-024110 | Feb 20, 2025 | Feb 18, 2025 |
| 4 | 4 | 0000950170-25-024114 | Feb 20, 2025 | Feb 18, 2025 |
| SCHEDULE 13G/A | — | 0001415889-25-004225 | Feb 14, 2025 | — |
| SCHEDULE 13G/A | — | 0001415889-25-003984 | Feb 14, 2025 | — |
| SCHEDULE 13G/A | — | 0001622627-25-000012 | Feb 13, 2025 | — |
| SCHEDULE 13G/A | — | 0001104659-25-012911 | Feb 13, 2025 | — |
| 4 | 4 | 0000950170-25-004164 | Jan 10, 2025 | Jan 7, 2025 |
| 8-K | 8-K | 0000950170-25-003286 | Jan 8, 2025 | — |
| 4 | 4 | 0000950170-24-137255 | Dec 17, 2024 | Dec 13, 2024 |
| 424B5 | 424B5 | 0001193125-24-279709 | Dec 16, 2024 | — |
| 8-K | 8-K | 0001193125-24-279715 | Dec 16, 2024 | Dec 15, 2024 |
| 8-K | 8-K | 0000950170-24-135602 | Dec 12, 2024 | — |
| 8-K | 8-K | 0000950170-24-132883 | Dec 3, 2024 | — |
| SC 13G/A | SC 13G/A | 0001104659-24-119338 | Nov 14, 2024 | — |
| SC 13G/A | SC 13G/A | 0001104659-24-117756 | Nov 13, 2024 | — |
| SC 13D/A | NEW ENTERPRISE ASSOCIATES 16, L.P. / TREVI THERAPEUTICS, INC. -- SCHEDULE 13D/A( | 0001072613-24-000813 | Nov 8, 2024 | — |
| SC 13G/A | SC 13G/A | 0001193125-24-251791 | Nov 6, 2024 | — |
| 8-K | 8-K | 0000950170-24-122316 | Nov 6, 2024 | — |